Monitoring progression of primary progressive aphasia: current approaches and future directions

Daisy Sapolsky1,2,3, Kimiko Domoto-Reilly1,4,5, Alyson Negreira1,2, Michael Brickhouse1,2, Scott McGinnis1,4,5 & Bradford C Dickerson1,2,4,5,6,7

Practice Points

- Initial assessment of patients with suspected primary progressive aphasia should include: detailed history from patient and informant; neurologic examination; speech and language assessment; neuropsychiatric assessment; neuropsychological evaluation; brain imaging with MRI and possibly fluorodeoxyglucose (FDG)-PET or single photon emission computed tomography; possibly other studies such as cerebrospinal fluid analysis.

- Longitudinal monitoring should include a subset of these assessments every 6 months to 1 year, with more frequent brief symptom-focused check-ups.

- Referral for enrollment in a research study at a specialized center should be considered.

- Treatment is symptomatic with both nonpharmacologic and pharmacologic approaches, including speech therapy, psychosocial therapy, and in some cases physical, occupational or cognitive therapy, and symptom-based targeted pharmacologic interventions.

Summary

Primary progressive aphasia (PPA) is a gradually progressive syndrome that robs patients of the ability to communicate. There are a variety of diagnostic challenges; international consensus has only recently been reached on the nomenclature for specific subtypes and there are a variety of underlying neurodegenerative pathologies. There are at present no established treatments, and efforts to develop treatments have been hampered by the lack of standardized methods to monitor progression of the illness. Although measures developed from work with stroke aphasia and with disorders such as Alzheimer’s disease have provided a valuable foundation for monitoring progression, PPA presents unique challenges to clinicians aiming to counsel patients and families on clinical status and prognosis, and to experts aiming to design clinical trials of potential interventions. Here we review some of the issues facing the field of PPA clinical research, summarize our current approach to monitoring progression of PPA and outline some ideas regarding goals for the development of better tools for this purpose.
Primary progressive aphasia (PPA) is a gradually progressive syndrome that was originally described in the late 1800s and has received growing attention since the 1980s, with a particular surge in the past 5–10 years [1–5]. For the most part, it is considered to be a form of frontotemporal dementia (FTD), although some forms of PPA may have other types of pathology. Although epidemiologic data on PPA are essentially non-existent, rough prevalence estimates from studies of frontotemporal dementia suggest that it may affect approximately 3–15/100,000 of the US population, or approximately 10,000–45,000 people in the USA. Scientifically, these disorders are of great interest, in part because they strike the language networks of the brain with surprising specificity, which may shed light on the pathobiology of neurodegenerative disorders and on the neurobiology of language function. From a clinical perspective, these disorders are devastating to the patients and families who experience them. One patient’s husband recently told us, “it is heartbreaking to lose the ability to carry on dialog with one’s spouse.” Yet for some individuals, despite the gravity of language impairment, it may be possible to find hope in the relative sparing of other cognitive abilities and the potential for the development of alternative communication strategies.

Unfortunately, at present, despite substantial effort in several clinical trials of pharmacologic agents [10–12] and preliminary efforts with rehabilitative techniques [13], we lack proof of efficacy of any form of treatment for PPA. Although there have been a number of important advances in clinical research related to PPA in the past few years, a critical barrier to the development of new treatments is the lack of standard assessment instruments that could be used in clinical trials. In this article, we will highlight some of the issues involved in the development of such instruments and initial efforts to develop such tools.

**Clinical constructs of PPA**

The core clinical phenotype of PPA is an insidious-onset, gradually progressive impairment of language production, object naming, syntax or word comprehension that is apparent during conversation or through speech and language assessments. There are several excellent descriptions of the recommended diagnostic approach [4,14].

In our practice we find it helpful to conceptualize PPA within the same general framework as Alzheimer’s disease (AD) and related neurodegenerative disorders, which are thought of as progressing in three clinical phases with respect to global function: asymptomatic/preclinical, mildly symptomatic/mild cognitive impairment and dementia (Figure 1). Because the pathophysiologic process of most neurodegenerative diseases is thought to take place over years prior to the development of symptoms, all of these conditions are thought to involve a phase in which neurodegenerative changes are developing in the brain but are not yet producing symptoms. In the earliest clinical phase, patients may describe increasingly effortful speech but may be able to perform well on many tests of language function. For some patients, this phase may last for a number of years. We have worked with several individuals whose professions involved heavy use of speech/language skills (e.g., writers and teachers) who were aware of problems in these areas for years before deficits were apparent on clinical assessment. As the condition progresses, impairments become evident on psycholinguistic tests, such as measures of naming, verbal fluency or picture description. At this clinical stage, many patients are still functioning relatively normally in complex activities of daily living and are capable of performing well on neuropsychological tests of cognitive domains other than language, such as memory, executive function or visuospatial ability. Nevertheless, by this time, neuronal loss and neuropathologic change have damaged core brain regions subserving language and a diagnosis can often be supported by demonstrating the expected abnormalities of brain structure or function with neuroimaging tests. Finally, patients enter a dementia phase in which other cognitive, behavioral and/or motor domains outside of language are affected and the person develops the need for assistance by others in daily activities (this phase is sometimes called ‘aphasic dementia’ or ‘PPA-plus’ [15]). Terminal events are those typically associated with dementia, such as aspiration pneumonia. Although it is often said that the course of the illness progresses over approximately 7–10 years from diagnosis to death, recent studies suggest that some forms of PPA may be slowly progressive for 12 or more years [16], with reports of up to 20 years depending on how early a diagnosis is made. Although very little research has been performed on prognosis in PPA, one study suggests that patients may maintain independence in activities of daily living for 6–7 years after the onset of symptoms, and that better functional outcomes may be associated with several baseline characteristics including fluent aphasia [17].
Once neuroprotective or disease-modifying medications aiming to slow disease progression are developed to the point that they can be tested in clinical trials, it would be ideal to initiate them as early as possible [18]. To approach this goal, we need to improve our capability to confidently identify individuals in the earliest stages of PPA. We also need to develop better instruments to grade the severity of the condition at baseline and to monitor decline over time. The development of such instruments is complicated by the clinicopathologic heterogeneity of PPA.

**Clinicopathologic subtypes of PPA**

The clinical syndrome of PPA has multiple subtypes, each of which appears to be probabilistically associated with a distinct type of neurodegeneration. In the last 5–10 years, three major subtypes of PPA have been defined—nonfluent/agrammatic, semantic and logopenic—each characterized by distinct profiles of language impairment and regional atrophy within the language networks [5,7,14,19,20]. Detailed descriptions of these subtypes are beyond the scope of this article, but a very brief description of their characteristics is as follows. The core features of the nonfluent/agrammatic variant of PPA are problems with grammar and syntax in language formulation and/or comprehension and effortful speech, often with speech sound errors and/or a motor speech impairment. The semantic variant of PPA is characterized primarily by prominent anomia and single-word comprehension deficits. The core features of the logopenic variant of PPA are deficits in word retrieval (in spontaneous speech and confrontation naming) and sentence repetition. Spontaneous speech is slow with frequent pauses due to significant word finding problems without frank agrammatism. Speech production deficits are therefore distinct from those of patients with the nonfluent/agrammatic variant, who also speak in a slow and halting manner, but with output that is dysprosodic with motor speech errors and/or agrammaticism. Despite substantial progress, there is still a need to better define these subtypes, including better methods to identify motor speech abnormalities, since these appear to be strong indicators of underlying tauopathies.

Although these subtypes are relatively easily recognizable in their typical forms, there is still a subset of patients who do not cleanly fit into one of these clinical subtype categories. Nevertheless, emerging data are beginning to suggest that the nonfluent/agrammatic, semantic and logopenic subtypes are largely, although not exclusively, associated with underlying tau, TDP-43 and Alzheimer pathologies, respectively [21]. Increasing effort is being devoted to trying to understand these clinicopathologic relationships, because if medications are developed to target specific molecular abnormalities, it will be critical to be able to identify PPA patients whose illness is associated with the particular abnormality the medication is targeting.

**Monitoring progression of overall clinical status**

Once a diagnosis of PPA is made, an important goal for the clinician is to determine the overall level of impairment, which will serve as a baseline against which longitudinal monitoring can be performed. In our practice and in the National Alzheimer’s Coordinating Center Uniform Data Set methodology (although there is still no consensus on this issue in the broader...
PPA community), an initial objective is to determine whether the patient would fit the designation of mild cognitive impairment or dementia, optimally via a structured clinical interview with the patient and someone who knows the patient well, typically a spouse or adult child. Questionnaire-based instruments can be helpful for this purpose, particularly those that aim to ascertain the type and degree of impairments in instrumental and basic activities of daily living [22–25]. Overall level of impairment can be graded using a variety of clinician-rated scales, such as the Clinical Dementia Rating scale [26] with the supplemental Language and Behavior ratings, the Clinician Global Impression of Change [27] and related measures of global dementia severity.

It is more challenging to utilize performance-based tests, such as the Mini-Mental State Exam, Addenbrooke’s Cognitive Exam (ACE), Alzheimer’s Disease Assessment Scale or neuropsychological test batteries, in part because of the effects of language deficits on nonlanguage domains of performance [27]. While we believe these evaluations are useful for a variety of purposes, we always encourage the patient to use his/her most functional response modality, which may be writing. Even then, a language deficit can be as problematic in writing as in speech, and may impede the patient’s ability to display his knowledge. Therefore, we have added multiple-choice response options to tests for measuring orientation, memory and other abilities. The National Alzheimer’s Coordinating Center Uniform Data Set workgroup is developing a Frontotemporal Dementia Module that should provide additional insights with respect to performance-based instruments. With these caveats in mind, however, a recent study demonstrated the value of the ACE in monitoring longitudinal change over time in patients with PPA [28].

**Monitoring progression of speech & language impairment**

Patients with PPA seek medical attention at different levels of severity – some patients seek neurologic/language evaluation at a very mild stage while others are surprisingly impaired by the first evaluation – and the rate at which symptoms progress varies considerably across patients (Figure 1). Therefore, the first step in monitoring speech/language is a comprehensive baseline assessment that goes beyond the language components of general cognitive measures used in AD. The baseline speech/language assessment provides key information to determine clinical subtype, which will be increasingly important as clinical trials targeting specific pathologies become available. The baseline assessment, if sensitive enough, might reveal the earliest speech/language signs and symptoms and help us to identify those patients who meet inclusion criteria for a trial. Furthermore, knowing the baseline level of impairment is necessary to determine the efficacy of interventions including drug treatments or speech/language therapy.

Information from baseline and monitoring measures is also crucial for patient/family education regarding diagnosis, current level of severity and prognosis. We are often asked questions such as, “How long until I won’t be able to speak at all?”, “Will I be able to understand even if I can’t speak?” or “Will my wife know how to use objects even if she can’t understand words?” As we learn more about the rate of change and evolution of language symptoms in PPA we will be better equipped to advise individuals as they plan for the future, as well as to help prepare them on an emotional/psychological level for future decline. Monitoring symptom severity and the emergence of new impairments is also critical for planning speech/language therapy and use of alternative communication strategies and devices.

Speech/language assessment can be carried out using a variety of performance-based tests from stroke aphasiology, such as the Western Aphasia Battery (WAB) [29] and Boston Diagnostic Aphasia Examination (BDAE) [30], pediatric speech–language pathology, such as the Curtiss–Yamada Comprehensive Language Evaluation–Receptive (CYCLE) [20], and tools recently developed for the PPA population, including the Northwestern Anagram Test (NAT) [31]. A motor speech exam is also typically carried out to determine the presence of apraxia of speech, which can be the presenting symptom in the nonfluent/agrammatic subtype or may be a distinct subtype [32,33]. See Table 1 for examples of these instruments.

We have found that performance-based testing is only one component of the evaluation. There are often discrepancies between test performance and ability to communicate in daily life, which we observe directly or learn about through interviewing the partner. In addition, psycholinguistic measures typically do not
Award credit for use of alternative communication strategies and compensatory efforts, which can significantly improve a patient's functional communication ability. We therefore consider the partner interview an important part of the assessment, and also obtain questionnaires about daily communication functioning from the partner (and patient when possible).

To integrate these sources of information, we recently developed a clinical rating scale that expanded upon the Clinical Dementia Rating (CDR) Supplemental Language rating scale [27], the Progressive Aphasia Severity Scale (PASS) [34]. The scale is used to rate presence and severity of impairment (0 = normal to 3 = severe impairment) in ten domains of language (Table 2). Ratings are made using the clinician’s best judgment of the overall level of impairment in each domain, based on information from a structured interview with the patient and partner, and from the language assessment. The ratings represent a snapshot of the patient's overall functioning in daily life in discrete domains of speech/language, and can be used at baseline and as a monitoring tool. There is also a functional communication domain, which takes into account the patient's ability to communicate despite the impairment (i.e., ability to use compensatory strategies). The scores in each domain can be summed to give a PASS Sum-of-Boxes measure, analogous to the CDR Sum-of-Boxes measure, representing a finer grading of overall level of impairment.

Table 1. Examples of psycholinguistic test instruments, by domain of function, commonly used to assess and monitor primary progressive aphasia.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Psycholinguistic test instruments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Articulation</td>
<td>Apraxia Battery for Adults, motor speech exam</td>
</tr>
<tr>
<td>Fluency</td>
<td>BDAE seven-point scale for phrase length, WAB Fluency, Grammatical Competence and Paraphasias Scale, clinician impression of fluency from spontaneous speech and picture descriptions</td>
</tr>
<tr>
<td>Syntax/grammar</td>
<td>BDAE seven-point scale for grammatical form, WAB Fluency, Grammatical Competence and Paraphasias Scale, Northwestern Anagram Test, analysis of language samples</td>
</tr>
<tr>
<td>Word retrieval</td>
<td>BNT, phonemic/category fluency tasks</td>
</tr>
<tr>
<td>Repetition</td>
<td>WAB and BDAE repetition tasks (words, phrases, sentences)</td>
</tr>
<tr>
<td>Auditory comprehension</td>
<td>WAB and BDAE following commands tasks, BDAE Complex Ideational Material, PAL Sentence Comprehension, CYCLE Sentence–Picture Matching</td>
</tr>
<tr>
<td>Single word comprehension</td>
<td>BDAE Word Comprehension, WAB Auditory Word Recognition, CSB Category Comprehension, PALPA Spoken Word–Picture Matching, Peabody Picture Vocabulary Test</td>
</tr>
<tr>
<td>Reading and writing</td>
<td>WAB and BDAE written language tasks</td>
</tr>
</tbody>
</table>

BDAE: Boston Diagnostic Aphasia Examination; BNT: Boston Naming Test; CSB: Cambridge Semantic Battery; CYCLE: Curtiss–Yamada Comprehensive Language Evaluation–Receptive; PAL: Psycholinguistic Assessment of Language; PALPA: Psycholinguistic Assessments of Language Processing in Aphasia; WAB: Western Aphasia Battery.

Table 2. Domains of the Progressive Aphasia Severity Scale.

<table>
<thead>
<tr>
<th>PASS domain</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Articulation</td>
<td>Ability to say sounds and syllables accurately and effortlessly</td>
</tr>
<tr>
<td>Fluency</td>
<td>Degree to which speech flows easily or is interrupted by hesitations, fillers, pauses; reduced fluency is associated with decreased phrase length and words per minute</td>
</tr>
<tr>
<td>Syntax and grammar</td>
<td>Use of word forms (run, ran), functor words (the, an), and word order when forming phrases and sentences in most used modality (speech or writing)</td>
</tr>
<tr>
<td>Word retrieval and expression</td>
<td>Ability to express the intended word through primary modality (speech or writing)</td>
</tr>
<tr>
<td>Repetition</td>
<td>Ability to repeat words, phrases, sentences; difficulty should not be attributable to working memory problem; do not penalize for sound distortions resulting from apraxia of speech or dysarthria</td>
</tr>
<tr>
<td>Auditory comprehension</td>
<td>Ability to understand spoken phrases and sentences (e.g., conversation, commands)</td>
</tr>
<tr>
<td>Single-word comprehension</td>
<td>Ability to understand spoken or written single words</td>
</tr>
<tr>
<td>Reading</td>
<td>Ability to decode and understand written material; difficulty should not be attributable to an elementary visual problem</td>
</tr>
<tr>
<td>Writing</td>
<td>Ability to write and spell; difficulty should not be attributable to an elementary motor problem</td>
</tr>
<tr>
<td>Functional communication</td>
<td>Ability to communicate despite the speech/language impairment; ability to compensate for impairment</td>
</tr>
</tbody>
</table>

Each language domain is rated on a scale of 0 (normal), 0.5 (questionable or very mild impairment), 1 (mild impairment), 2 (moderate) or 3 (severe). PASS: Progressive Aphasia Severity Scale.
Because the PASS allows us to rate individual domains of speech/language, it captures the pattern of relative strengths and weaknesses at baseline and at each successive evaluation. We use it as a tool to monitor the emergence of problems in initially unaffected areas, and the rate at which impaired domains worsen. We are currently investigating whether baseline PASS assessment data are useful for predicting the domains of most prominent impairment (and relative preservation) over the subsequent 2–4 years, which would be very valuable for discussions about prognosis. For example, we rated patient A over the course of 2 years (Figure 2). Ratings were relatively stable in articulation, syntax and fluency, whereas they declined in word retrieval, auditory comprehension and single-word comprehension, the areas that were initially most impaired. That is, the patient declined most significantly in the areas that were initially affected while preserved domains remained areas of strength. This is highly clinically relevant as patients and families often ask whether problems will develop in areas not initially affected. In the case of patient B, ratings were stable or changed only slightly (0.5) over 2 years, indicating a relatively slow rate of progression with many areas of relative strength (Figure 2). This information can be used to provide feedback to the patient about rate of progression and areas of stability, as well as to help clinicians plan speech therapy that targets the problem domains and capitalizes on the areas of strength.

More information about the PASS, including questionnaires and training materials, can be found on the MGH Frontotemporal Dementia Unit website [101]. We are currently working with collaborators to further assess the multicenter reliability of this instrument.

**Monitoring progression of additional neurologic impairments**

At initial assessment, a complete neurologic examination should be performed, in part to assess for evidence of an alternate etiology such as cerebrovascular or mass lesions. Such an evaluation can prove especially helpful if the patient is unable or unwilling to undergo brain imaging. In addition, the presence or absence of abnormalities on the neurologic exam can provide additional evidence in support of (limb apraxia) or against (cerebellar ataxia and choreoathetosis) the PPA diagnosis [7]. Some patients exhibit subtle motor abnormalities very early in the course of PPA. The Frontal Assessment Battery (FAB) can be particularly useful in the neurologist’s office for further assessing frontal systems functions [35].

As the disorder progresses, other neurologic findings may become evident; this stage of the illness has been termed PPA-plus [15]. In many cases, the disorder may evolve into an aphasic dementia with other cognitive, behavioral and functional impairment. Neurologic and neuropsychiatric monitoring is particularly important in this phase of the illness because the family often needs to be counseled about these new sources of functional impairment and the possible need for additional treatments (e.g., pharmacologic interventions for behavioral symptoms or physical or occupational therapy for gait or eye–hand coordination abnormalities).

Executive dysfunction is common as PPA progresses, and often becomes obvious in daily life as patients stop using compensatory strategies effectively. Semantic dementia in particular is often associated with later emergence of behavioral and attentional disturbances similar to those observed in behavioral variant frontotemporal dementia. Assessments such as the Behavior Rating Inventory of Executive Function–Adult Version (BRIEF-A) [36] and the Frontal Systems Behavior Scale (FrSBe) [37] are useful scales that engage both patients and families in rating specific subcomponents of executive functions in daily life. These questionnaires complement standard neurologic and neuropsychologic evaluations of attention and executive function (e.g., digit/spatial span, Trail-making test, Luria motor sequences and Tower of London test).

Motor abnormalities may contribute substantially to overall functional disability in later stages of the illness. The nonfluent/agrammatic variant may be associated with the development of motor abnormalities consistent with progressive supranuclear palsy (gait impairment, axial rigidity and eye movement abnormalities) or corticobasal degeneration syndrome (asymmetric rigidity, alien limb and reflex myoclonus) [38]. Motor neuron disease findings (e.g., atrophy, weakness or fasciculations) may also arise and should be screened for in the neurologic examination. Swallowing difficulties are common in middle and later stages of PPA; a formal swallowing evaluation and consultation regarding eating and nutrition may be indispensable in many patients.
Monitoring progression of neuropsychiatric symptoms & psychosocial support

Neuropsychiatric symptoms, such as mood disturbances, compulsive behavior, apathy, disinhibition, irritability and agitation are common in PPA [2,39]. Although some PPA patients exhibit minimal neuropsychiatric symptoms, for others this can be a major source of disability. Some patients with PPA develop prominent depression and at least one case in our practice developed suicidality, while others may be euphoric and disinhibited. In our experience, apathy is very common. Neuropsychiatric symptoms in PPA evolves as the disorder progresses, with some symptoms waxing and others waning [39]. Since many of these symptoms reduce quality of life and may be possible to ameliorate with existing interventions, it is critical to monitor them. We find that questionnaire-based instruments such as the Neuropsychiatric Inventory (NPI) Questionnaire [40], the Cambridge Behavioral Inventory [41] or the Frontal Behavioral Inventory [42] are particularly useful in this regard. To monitor these symptoms, we suggest an initial comprehensive assessment at baseline using one of these instruments supplemented with a structured interview, with additional similar monitoring every 3–6 months or more frequently depending on the nature and severity of symptoms. We believe that the impressions of experienced clinicians regarding these symptoms are critical; a new clinician-rated instrument based on the NPI was recently developed for these purposes [43]. The involvement of a psychiatrist or neuropsychiatrist is often invaluable.

In addition to the dissolution of language, the presence of neuropsychiatric symptoms can lead to significant psychosocial distress for both patients and caregivers. As a consequence, caregivers often develop substantial physical, psychological, social and/or financial burdens [44]. Little research has been carried out with respect to the psychosocial burden of PPA [45]. Similarly, it is unclear whether specific methods are useful for the reduction of these burdens. To address these issues, we and other specialty groups offer various types of support group meetings for caregivers of patients with PPA; some of these also involve patients [45]. The support groups address emotion-centered coping strategies as well as specific problem-solving techniques that address the management of patients’ behaviors. Some support groups target partner-oriented communication strategies in PPA.

Imaging biomarkers for diagnosis & monitoring of progression

Imaging biomarkers of brain anatomy, function and molecular composition are already essential tools for diagnosis of most neurodegenerative...
diseases and will almost certainly be critical for monitoring progression. For the purposes of clinical trials, these tools can be thought of as useful for identifying a relatively homogenous sample of participants (i.e., for the identification of disease-specific brain abnormalities and the exclusion of those lacking typical disease-associated abnormalities, much as is done in stroke or multiple sclerosis). They can also be thought of as potential outcome measures, although the clinical validation requirements called for by the US FDA make this a taller hurdle. Readers interested in a detailed discussion of some of the issues in the field of AD are referred to a previous publication [46].

Although routine clinical MRI scans in patients with mild PPA are often interpreted as within normal limits, careful visual inspection of specific cortical regions can often provide the clinician with evidence of subtle atrophy in critical nodes of the language network. The ability to see these regions clearly depends heavily on the type of MRI scan obtained, and we typically employ a high-resolution (1-mm isotropic) coronal T1-weighted scan, which is a sequence that is becoming much more widely available on common MRI platforms; this type of sequence should be requested in the MRI protocol and clinicians should review the results directly themselves in consultation with a radiologist or other imaging expert. See Figure 3 for case examples.

There has been great progress aimed at mapping focal brain abnormalities in PPA and relating these abnormalities to types of language deficits by comparing groups of clinically characterized patients to controls or to other disease groups [20,47,48]. Most of the techniques used in such studies that aim to map atrophy and rates of progression in PPA are at present still basic imaging neuroscience research methodology, and are not yet tools that are available for clinical use. One such technique under development in our group consists of cortical thickness mapping, which has the ability to measure the thickness of the cerebral cortex with submillimeter precision. This method can be used to localize regions of cortical atrophy in patient groups compared with controls. In contrast to AD, in which the ‘signature’ of regional cortical atrophy includes the medial and lateral temporal lobe, the medial and lateral parietal lobe, and often frontal atrophy with a relatively symmetric pattern [49], PPA typically has a distinct asymmetric perisylvian atrophy pattern (Figure 4). Although these patterns appear to be quite consistent across centers [19,34,50], there has been little effort aimed at localizing and quantifying abnormalities in single individuals. If we aim to use quantitative imaging measures as diagnostic markers, the translation of these imaging methods into tools that can be applied to individual patients will be crucial. Some of these research imaging methods could potentially be translated into tools that can be used clinically in individual patients, but the appropriate reliability and validity studies need to be performed.

Although both structural MRI and fluorodeoxyglucose (FDG)-PET metabolic measures have been used in studies of PPA, there has never been a systematic head-to-head comparison of the relative sensitivity and specificity of these imaging measures in PPA. Do they provide...
complementary or redundant information? In the field of AD, it appears that MRI and FDG-PET provide complementary information that, together, improve the sensitivity and specificity of diagnosis beyond that provided by either modality alone [51]. Since FDG-PET is becoming more widely available and is approved by Medicare for reimbursement for the differential diagnosis of AD versus frontotemporal dementia (of which PPA is considered a subtype), it is important to determine the potential benefits of this type of scanning in PPA, particularly since it is still costly.

In addition to FDG-PET, there are several emerging MRI-based measures of brain function, including task-related functional MRI, functional connectivity MRI and perfusion MRI (arterial spin-labeled MRI). For the most part, these are all currently innovative basic imaging science techniques being used to investigate aspects of brain function, and have not yet been subjected to reliability, validity or longitudinal studies to determine their potential for translation into useful tools for clinical trials.

As mentioned earlier, recent post-mortem studies of the pathologic substrates of PPA and related disorders have demonstrated that a substantial portion of patients have AD pathology [52,53], which has been shown in vivo using Pittsburgh compound B (PiB) PET amyloid imaging [54], a novel imaging marker of fibrillar amyloid pathology being used in a variety of research settings but not yet in clinical use. Although a small percentage of patients with the semantic variant of PPA have evidence of AD pathology, it appears that most patients with the logopenic subtype of PPA harbor AD pathology, suggesting that this form of PPA may be an atypical variant of AD. While there are a large number of questions that deserve investigation as follow-up to these initial studies, it is clear that investigations attempting to identify in vivo clinical and imaging markers for use in clinical trials need to include measures that aim to determine whether there are specific characteristics unique to PPA patients with Alzheimer pathology. Ultimately, it will be important to decide whether these patients should be directed toward disease-modifying clinical trials for AD even though their clinical phenotype is in most cases quite different from that of typical AD. Thus, this imaging method needs to be included in the translational efforts aimed at identifying an optimal set of imaging markers for use in PPA clinical trials.

Efforts are ongoing to develop PET ligands that label fibrillar tau protein, with initial efforts beginning to show promise [55,56]. Ultimately, it may be possible to use molecular markers to ‘triangulate’ the three major subtypes of PPA with the goal of determining whether nonfluent/agrammatic patients exhibit tau-positive PET signals but an absent PiB signal consistent with underlying tau pathology, logopenic patients exhibit elevated PiB and tau signal consistent with AD pathology, and semantic patients exhibit no uptake of PiB or tau ligands suggestive of underlying TDP-43 pathology. These PET findings could then be investigated in relation to the quantitative MRI measures described earlier to determine how well the MRI measures predict molecular abnormalities. The impact of this type of analysis would be to determine whether these

![Figure 4. Cortical thickness analysis as an imaging biomarker of primary progressive aphasia. Quantitative analysis of MRI data is still a research tool but it is becoming more apparent that these methods need to be translated into clinically efficient tools, since measures of neuroanatomic abnormalities can be very useful as biomarkers for diagnosis and probably longitudinal monitoring. (A) The regional pattern of cortical thinning in primary progressive aphasia, shown here for a group of 23 primary progressive aphasia patients (including all three subtypes) versus controls, is highly asymmetric and localized in the perisylvian regions of the language networks. (B) The map is generated from a semiautomated measurement of the thickness of the cerebral cortex; comparison of the cortical thickness of a group of patients versus a group of controls may reveal regionally specific thinning even though the magnitude of such thinning may be 0.1–0.2 mm.](image-url)
additional but expensive molecular markers are needed to increase the specificity of diagnosis, or whether specificity is nearly as good using MRI (and possibly FDG-PET) measures alone. This will be essential information for the planning of treatment trials of compounds that are targeted toward specific molecular abnormalities, which is the case for a growing number of compounds.

If our long-term goal is to intervene in PPA using forms of disease-modifying therapy, or even to investigate potential plastic responses to forms of speech and language therapy, we need markers of brain structure and function that are sensitive to disease progression. We know that different types of PPA progress at different rates; new data indicate that the nonfluent/agrammatic variant progresses relatively rapidly and the semantic variant more slowly [16]. Furthermore, individual patients clearly vary with respect to each other in the level of impairment at initial presentation and in the rate of progression.

Several natural history studies are ongoing in which longitudinal MRI and in some cases PET data are being collected in patients with PPA and related disorders. One goal is to generate data that would enable power calculations to be performed to estimate sample size for disease-modifying clinical trials, much as has been done in AD research; initial data in PPA look promising [57,58]. Baseline imaging measures are also being investigated for their potential as predictive markers of clinical or functional–anatomic change, with the goal of determining whether some of these measures could be indicators of patients who may be ‘rapid progressors’, since this population would be an ideal target for clinical trials. See Figure 5 for an example of these types of longitudinal MRI measures.

Other biomarkers
In addition to imaging biomarkers, work is in progress to identify biofluid markers in blood or cerebrospinal fluid (CSF). At present, these are largely targeting CSF amyloid-β and tau abnormalities that are consistent with AD pathology, and are primarily directed at early diagnosis and prognostication, as opposed to monitoring of disease progression. A combination of elevated tau and phosphorylated tau accompanied by reduced amyloid-β is strongly suggestive of AD pathology [59]. In PPA patients exhibiting such a CSF profile, AD pathology would be strongly suspected and such patients might then be considered as potential candidates for certain types of AD clinical trials. This CSF molecular biomarker of AD is at present the only such approach that is routinely clinically available for this purpose and reimbursable by many American third-party payors.

With regard to the detection of CSF markers of non-AD tau or TDP-43 pathology, few studies have been conducted to date. Investigations of tau abnormalities are somewhat controversial, with some studies showing elevated tau and others showing reductions of tau. CSF assays for TDP-43 have recently been developed, and their preliminary use so far suggests that further work is needed. Finally, a variety of other proteins are being studied to investigate their potential use in understanding the pathobiology of the underlying diseases and differential diagnosis or monitoring [5].

Conclusion & future perspective
We hope to see the development of efficacious interventions for PPA in the next decade. These treatments should improve function, slow progression or both. Some of these treatments, such as specific forms of speech and language therapy, may be developed specifically for PPA and may target all individuals with PPA. Some drug treatments, such as neuroprotective medications, may also focus on this population or the broader population of patients with forms of frontotemporal dementia or kindred disorders. There is also increasing effort being devoted to the development of compounds targeting specific molecular abnormalities that contribute to the pathologic neurodegenerative process of these disorders, such as abnormalities of tau phosphorylation and aggregation.

For these latter compounds, we need to address several critical issues in clinical trial design. First, how do we identify patients with the specific biologic abnormality? This will likely involve a combination of clinical phenotype and one or more types of biomarkers. For example, a clinical trial of a tau agent in frontotemporal dementia could possibly enroll patients with a diagnosis of behavioral-variant or language-variant frontotemporal dementia and biomarker evidence of a tau abnormality. Next, how do we monitor patients to determine whether the treatment is working? We envision the need for a multifaceted approach involving multiple types of clinical instruments as well as imaging or other biomarkers. The clinical instruments need to encompass the spectrum of abnormalities with reasonable sensitivity and specificity. Besides global functional measures,
such as the Clinical Global Impression of Change or the CDR scale, we also need domain-specific scales of impairment, such as the PASS described here. We also need standardized performance-based measures, probably including both a general cognitive measure such as the Mini-Mental State Exam or a similar measure, as well as domain-specific measures such as naming, fluency or other language tasks. Finally, we will also need to include ratings or measures of other domains, particularly motor and behavioral/affective function since these abilities are typically involved as PPA progresses. Ongoing longitudinal studies will provide critical natural history data that will be useful for planning such trials.

We are optimistic that the development of all of these kinds of tools is a major goal of the international research community working on PPA, but we continue to need to harmonize methods and invest in infrastructure to encourage data sharing, such as the IMPPACT website and registry for PPA [102]. Through such efforts, and in partnership with federal agencies, industry and private foundations including the Association for Frontotemporal Dementia, we hope to see the burdens of PPA on patients and families lessened over the coming years.

Acknowledgements

The authors express special appreciation to the participants in our program and their families for their valuable contributions.
Financial & competing interests disclosure

This work was supported by grants from the NIA (R01-AG29411, R21-AG29840 and P50-AG005134), and the Alzheimer’s Association. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Bibliography

Papers of special note have been highlighted as:

- of interest
- of considerable interest


6 Summarizes current knowledge of the relationships between clinical symptoms and biological aspects of these disorders.


8 Contains a practical guide to the approach to diagnosis of primary progressive aphasia (PPA), as well as reviewing other clinical and biological aspects of these disorders.


14 Provides the new framework for the classification and diagnosis of PPA subtypes.


29 Demonstrates an approach to the design of longitudinal clinical research in PPA and behavioral variant frontotemporal dementia with an emphasis on the possibilities and limitations for translating these methods for use in clinical trials.


31 Provides evidence that performance-based testing of multiple cognitive functions can detect longitudinal decline in PPA.

32 Kertesz A: *Western Aphasia Battery*. Grune and Stratton, NY, USA (1982).

Monitoring progression of primary progressive aphasia: current approaches and future directions


Analyzes clinical, imaging and pathological relationships in patients with PPA.


Provides evidence regarding longitudinal change over time in clinical and brain imaging measures in PPA and behavioral variant frontotemporal dementia, including sample size estimates to assist in the design of clinical trials.


Websites

101 MGH Frontotemporal Disorders (FTD) Unit www.frd-boston.org
102 IMPPACT website and registry for PPA www.ppaconnection.org